Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.

 

whitepaper image
download icon

Download whitepaper

How AI and real-world data are transforming clinical trials

Clinical trials are evolving. Traditional randomized controlled trials (RCTs) have long been the gold standard in clinical research, but they are increasingly challenged by slow timelines, high costs, and limited generalizability. Meanwhile, vast volumes of real-world data (RWD), such as electronic health records, genomic datasets, and patient-reported outcomes, are now being captured across health systems. Alongside these data sources, artificial intelligence (AI) tools are becoming increasingly capable of extracting insights at speed and scale.

In this whitepaper, we highlight how RWD and AI are reshaping the way clinical trials – particularly in precision medicine – are designed, executed, and optimized. This includes advances in trial design such as target trial emulation, synthetic control arms, and the use of AI to refine eligibility criteria, predict treatment response, and accelerate patient matching.

Download now to learn more.

AIRWDgroup